UPTAKE OF ANTIRETROVIRAL THERAPY AMONG HIV-INFECTED PREGNANT WOMEN AND ITS IMPACT ON HIV MOTHER-TO-CHILD TRANSMISSION IN MBEYA, TANZANIA. (12th February 2017)
- Record Type:
- Journal Article
- Title:
- UPTAKE OF ANTIRETROVIRAL THERAPY AMONG HIV-INFECTED PREGNANT WOMEN AND ITS IMPACT ON HIV MOTHER-TO-CHILD TRANSMISSION IN MBEYA, TANZANIA. (12th February 2017)
- Main Title:
- UPTAKE OF ANTIRETROVIRAL THERAPY AMONG HIV-INFECTED PREGNANT WOMEN AND ITS IMPACT ON HIV MOTHER-TO-CHILD TRANSMISSION IN MBEYA, TANZANIA
- Authors:
- Masenza, Issa Sabi
Geisenberger, Otto
Agrea, Peter
Maboko, Leonard
Rwegoshora, France
Mahiga, Hellen
Olomi, Willyhelmina
Hoelscher, Michael
Kroidl, Arne - Abstract:
- Abstract : Background: Maternal viral load (VL) and immunological status are important risk factors for mother-to-child transmission of HIV. In line with WHO recommendations (Option B+), Tanzania introduced the initiation of life long antiretroviral therapy (ART) in pregnant women in 2013. We present the uptake of ART and its impact on mother-to-child transmission. Methods: Between July 2015 and June 2016 data were obtained from HIV-infected pregnant women participating in the ongoing BABY Study ( ClinicalTrials.gov Identifier: NCT02545296 ), which evaluates point-of-care testing in HIV Early Infant Diagnosis (HEID). Women were enrolled at the time of delivery, and neonates were followed-up until 6 weeks post-partum. Maternal HIV-RNA was assessed at delivery; neonatal HIV diagnosis was performed using the Cepheid Xpert point-of-care test and confirmed by qualitative dry blood spot HIV-DNA (Roche COBAS TaqMan). Results: In total 415 HIV-infected pregnant women were enrolled (median age 29 years). Nearly all women had attended antenatal care (96.4%); in 245 (59%) HIV was first diagnosed during pregnancy, and in 63.8% ART was initiated within 1 week following diagnosis. At the time of delivery 368 (88.7%) women were on ART, HIV-RNA >1000 copies/mL were detected in 78 (18.9%) and a CD4 count <200 cells/µL in 63 (15.2%). The overall mother-to-child HIV transmission rate was 2.4% (10/415) and 7/10 neonates were HIV diagnosed at the time of birth correctly identified byAbstract : Background: Maternal viral load (VL) and immunological status are important risk factors for mother-to-child transmission of HIV. In line with WHO recommendations (Option B+), Tanzania introduced the initiation of life long antiretroviral therapy (ART) in pregnant women in 2013. We present the uptake of ART and its impact on mother-to-child transmission. Methods: Between July 2015 and June 2016 data were obtained from HIV-infected pregnant women participating in the ongoing BABY Study ( ClinicalTrials.gov Identifier: NCT02545296 ), which evaluates point-of-care testing in HIV Early Infant Diagnosis (HEID). Women were enrolled at the time of delivery, and neonates were followed-up until 6 weeks post-partum. Maternal HIV-RNA was assessed at delivery; neonatal HIV diagnosis was performed using the Cepheid Xpert point-of-care test and confirmed by qualitative dry blood spot HIV-DNA (Roche COBAS TaqMan). Results: In total 415 HIV-infected pregnant women were enrolled (median age 29 years). Nearly all women had attended antenatal care (96.4%); in 245 (59%) HIV was first diagnosed during pregnancy, and in 63.8% ART was initiated within 1 week following diagnosis. At the time of delivery 368 (88.7%) women were on ART, HIV-RNA >1000 copies/mL were detected in 78 (18.9%) and a CD4 count <200 cells/µL in 63 (15.2%). The overall mother-to-child HIV transmission rate was 2.4% (10/415) and 7/10 neonates were HIV diagnosed at the time of birth correctly identified by point-of-care testing. HIV-RNA >1000 copies/ml irrespectively of ART and low CD4 count <200 cells/μL were associated with higher risk of neonatal HIV transmission. Conclusions: Despite the implementation of life-long ART in all pregnant women, reduction of HIV transmission from mother to child is still sub-optimal. High HIV-RNA as the main risk factor for HIV transmission irrespective of maternal ART points to the need for maternal VL screening during the antenatal period. … (more)
- Is Part Of:
- BMJ global health. Volume 2(2017)Supplement 2
- Journal:
- BMJ global health
- Issue:
- Volume 2(2017)Supplement 2
- Issue Display:
- Volume 2, Issue 2 (2017)
- Year:
- 2017
- Volume:
- 2
- Issue:
- 2
- Issue Sort Value:
- 2017-0002-0002-0000
- Page Start:
- A48
- Page End:
- A49
- Publication Date:
- 2017-02-12
- Subjects:
- World health -- Periodicals
362.105 - Journal URLs:
- http://www.bmj.com/archive ↗
http://gh.bmj.com/ ↗ - DOI:
- 10.1136/bmjgh-2016-000260.129 ↗
- Languages:
- English
- ISSNs:
- 2059-7908
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 18504.xml